Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. More Details
High growth potential with adequate balance sheet.
Share Price & News
How has Cochlear's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CHEO.Y has not had significant price volatility in the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: CHEO.Y underperformed the US Medical Equipment industry which returned 13.7% over the past year.
Return vs Market: CHEO.Y underperformed the US Market which returned 10.9% over the past year.
Price Volatility Vs. Market
How volatile is Cochlear's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Cochlear undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: CHEO.Y ($71.48) is trading above our estimate of fair value ($43)
Significantly Below Fair Value: CHEO.Y is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CHEO.Y is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: CHEO.Y is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CHEO.Y's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CHEO.Y is overvalued based on its PB Ratio (9.5x) compared to the US Medical Equipment industry average (3.7x).
How is Cochlear forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CHEO.Y is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: CHEO.Y is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CHEO.Y's is expected to become profitable in the next 3 years.
Revenue vs Market: CHEO.Y's revenue (11.3% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: CHEO.Y's revenue (11.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CHEO.Y's Return on Equity is forecast to be high in 3 years time (20%)
How has Cochlear performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CHEO.Y is currently unprofitable.
Growing Profit Margin: CHEO.Y is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CHEO.Y is unprofitable, and losses have increased over the past 5 years at a rate of 4.3% per year.
Accelerating Growth: Unable to compare CHEO.Y's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CHEO.Y is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).
Return on Equity
High ROE: CHEO.Y has a negative Return on Equity (-17%), as it is currently unprofitable.
How is Cochlear's financial position?
Financial Position Analysis
Short Term Liabilities: CHEO.Y's short term assets (A$1.5B) exceed its short term liabilities (A$817.5M).
Long Term Liabilities: CHEO.Y's short term assets (A$1.5B) exceed its long term liabilities (A$356.7M).
Debt to Equity History and Analysis
Debt Level: CHEO.Y's debt to equity ratio (33.7%) is considered satisfactory.
Reducing Debt: CHEO.Y's debt to equity ratio has reduced from 59.6% to 33.7% over the past 5 years.
Debt Coverage: CHEO.Y's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: CHEO.Y is unprofitable, therefore interest payments are not well covered by earnings.
What is Cochlear current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CHEO.Y's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CHEO.Y's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CHEO.Y's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CHEO.Y's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: CHEO.Y is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CHEO.Y's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dig Howitt (53 yo)
Mr. Diggory William Howitt, also known as Dig, BE (Hons), MBA has been President of Cochlear Limited since July 31, 2017 and its Chief Executive Officer and Managing Director since January 3, 2018. Mr. How ...
CEO Compensation Analysis
Compensation vs Market: Dig's total compensation ($USD1.90M) is below average for companies of similar size in the US market ($USD7.46M).
Compensation vs Earnings: Dig's compensation has been consistent with company performance over the past year.
|CEO, MD||2.67yrs||AU$2.70m||0.070% |
|Chief Financial Officer||3.5yrs||AU$834.08k||0.00052% |
|Chief Technology Officer||2.83yrs||AU$1.12m||0.010% |
|President of EMEA & Latin American Region||no data||AU$1.39m||0.0076% |
|President of Americas Region||4.42yrs||AU$1.17m||0.0063% |
|President of Asia Pacific Region||4.17yrs||AU$713.42k||0.0038% |
|Chief Information Officer||5.17yrs||no data||no data|
|Head of Investor Relations||no data||no data||no data|
|Head of Corporate Communications||no data||no data||no data|
|Senior Vice President of Global Marketing||4.25yrs||no data||no data|
|Senior Vice President People & Culture||3.67yrs||no data||no data|
|Senior Vice President of Supply Chain & Operational Excellence||no data||no data||no data|
Experienced Management: CHEO.Y's management team is considered experienced (3.9 years average tenure).
|CEO, MD||2.67yrs||AU$2.70m||0.070% |
|Independent Non-Executive Director||13.58yrs||AU$238.69k||0% |
|Independent Non-Executive Director||0.67yr||AU$94.33k||0.0019% |
|Independent Non-Executive Director||15.08yrs||AU$237.07k||0% |
|Independent Chairman||10.17yrs||AU$509.39k||0% |
|Independent Non-Executive Director||5.67yrs||AU$259.52k||0% |
|Independent Non-Executive Director||10.08yrs||AU$265.85k||0% |
|Independent Non-Executive Director||3.75yrs||AU$246.92k||0.0016% |
|Independent Non-Executive Director||5.67yrs||AU$261.14k||0% |
|Non-Executive Independent Director||1.75yrs||AU$212.30k||0.0019% |
Experienced Board: CHEO.Y's board of directors are considered experienced (5.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.7%.
Cochlear Limited's company bio, employee growth, exchange listings and data sources
- Name: Cochlear Limited
- Ticker: CHEO.Y
- Exchange: OTCPK
- Founded: 1981
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: AU$13.289b
- Listing Market Cap: AU$9.340b
- Shares outstanding: 65.73m
- Website: https://www.cochlear.com
Number of Employees
- Cochlear Limited
- 1 University Avenue
- Macquarie University
- New South Wales
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CHEO.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Dec 1995|
|COH||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Dec 1995|
|OC5||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Dec 1995|
|COH||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Dec 1995|
|CHEO.Y||OTCPK (Pink Sheets LLC)||UNSPONSORD ADR||US||USD||Jan 2009|
Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7, Nucleus 6, Nucleus ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/25 05:56|
|End of Day Share Price||2020/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.